Market strategists reviewing OTLK stock forecast point to high cash burn rates as a limiting factor, balancing optimism on trial success against possible dilution risks. Is it risky? Absolutely – we’re talking about an enterprise with a market capitalization of only $32.64 million. However, analysts rate shares a unanimous strong buy with a $1.18 price target, up over 179%. We have global expertise in market analysis and in advisory and capital-raising services for corporations, institutions and governments. Short-term OTLK stock forecast sentiment has slightly improved after broader biotech indexes gained 3% last week, which often correlates with small-cap stock rallies in similar subsectors.
